Blog

DFMO

March 31st, 2017   |   Posted in Relapse, Treatment   |   By: Antonia Palmer   |   0 comments

DFMO is an interesting drug, and one that is currently being considered for a future clinical trial in Canada for children with neuroblastoma. There is a great deal to understand about this drug – both in how it works and the process for opening up a clinical trial in Canada.

» CONTINUE READING

G-CSF and Neuroblastoma

December 10th, 2015   |   Posted in Treatment   |   By: Antonia Palmer   |   0 comments

In May 2015, neuroblastoma families became increasingly concerned about the use of G-CSF in treatment due to emerging research findings. This article reviews that research in hopes of providing some clarity.

» CONTINUE READING

MIBG Therapy for High-Risk Neuroblastoma

June 1st, 2015   |   Posted in Treatment   |   By: Antonia Palmer   |   1 comment

The science and understanding of MIBG therapy for high-risk neuroblastoma continues to evolve and change. This article reviews past research, current practices and future directions of the treatment.

» CONTINUE READING

Counting the Cost

September 9th, 2014   |   Posted in Awareness   |   By: Aaron Hudson   |   6 comments

Your personal accountings of life tell a story and everyone’s numbers paint a different picture. This is an account of one 7-year-old boy in the battle against neuroblastoma cancer and what his numbers look like.

» CONTINUE READING

Interview with the Canadian Cancer Research Alliance (CCRA)

February 17th, 2014   |   Posted in Investment   |   By: Antonia Palmer   |   0 comments

Neuroblastoma Canada interviews two authors from the CCRA’s report on the current state of financial investment into pediatric cancer research in Canada.

» CONTINUE READING

Current and Future Strategies for Relapsed Neuroblastoma

July 19th, 2013   |   Posted in Relapse, Treatment   |   By: Antonia Palmer   |   1 comment

Navigating the options available for relapsed treatment is incredibly difficult and is done without a set of established and well-entrenched guidelines.

» CONTINUE READING

Back to Top